PLAC1: biology and potential application in cancer immunotherapy Jafar MahmoudianRoya GhodsAmir-Hassan Zarnani Review 05 June 2019 Pages: 1039 - 1058
Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma Shuo LiuZhen HanJoost J. Oppenheim Original Article Open access 10 April 2019 Pages: 1059 - 1071
Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses Zhen HanShuo LiuJoost J. Oppenheim Original Article Open access 03 June 2019 Pages: 1073 - 1085
Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer Yen-Lin ChenWen-Chien HuangManana Javey Original Article Open access 14 May 2019 Pages: 1087 - 1094
Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity Lindsey M. KuehmKyle WolfRyan M. Teague Original Article 18 May 2019 Pages: 1095 - 1106
Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma Pravin KesarwaniAntony PrabhuPrakash Chinnaiyan Original Article 22 May 2019 Pages: 1107 - 1120
Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors Katie M. LeickJoel PinczewskiCraig L. Slingluff Jr. Original Article 27 May 2019 Pages: 1121 - 1132
Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma Sonja LudwigChang-Sook HongTheresa L. Whiteside Original Article 28 May 2019 Pages: 1133 - 1141
An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice Richard F. JonesJoyce D. ReyesWei-Zen Wei Original Article 08 June 2019 Pages: 1143 - 1155
Clinicopathological implications of TIM3+ tumor-infiltrating lymphocytes and the miR-455-5p/Galectin-9 axis in skull base chordoma patients Jinpeng ZhouYang JiangZhitao Jing Original Article 13 June 2019 Pages: 1157 - 1169
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma Antoine Moya-PlanaRuth Gabriela Herrera GómezCaroline Robert Original Article 07 June 2019 Pages: 1171 - 1178
Pembrolizumab as first-line treatment for metastatic uveal melanoma Ernesto RossiMonica Maria PagliaraGiovanni Schinzari Original Article Open access 07 June 2019 Pages: 1179 - 1185
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases Yenny AngelaSebastian HaferkampRalf Gutzmer Original Article 11 June 2019 Pages: 1187 - 1194
Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells Wenjie GongJean-Marc HoffmannLeopold Sellner Original Article 08 June 2019 Pages: 1195 - 1209
First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1 Amit MahipalSamuel EjadiKunle Odunsi Clinical Trial Report 08 May 2019 Pages: 1211 - 1222
